C3a 70-77 (Complement 3a (70-77)) |
| カタログ番号GC31928 |
C3a 70-77 (Complement 3a (70-77)) は、C3a の COOH 末端に対応するオクタペプチドであり、C3a の特異性と 1 ～ 2% の生物学的活性を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 63555-63-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
The direct interaction of C3a(70-77) with human mononuclear leukocytes in culture results in a concentrationdependent inhibition of the generation of LIF evoked by mitogens and by the antigen SK-SD. The extent of suppression of LIF generation by C3a(70-77) is significant at concentrations of 10-7 M or higher and exceeds 75% at 10-6 M, irrespective of the stimulus[1]. C3a (70-77), an octapeptide corresponding to the COOH terminus of human C3a, exhibits the specificity and biologic activities of C3a. Although lacking 69 residues at the NH2 terminus, it maintains 1 to 2% of the activity of natural human C3a. C3a (70-77), Ala-Ser-HisLeu-Gly-Leu-Ala-Arg, induces histamine release and degranulation of rat mast cells, promotes contraction of guinea pig ileal tissue, and enhances vascular permeability in human skin. C3a (70-77) selectively desensitizes ileal smooth muscle to C3a but not to human C5a, a related anaphylatoxin. Conversely, C3a-(70-77) is unable to contract ileal smooth muscle pretreated with natural C3a. This cross-desensitization indicates a specific interaction of C3a (70-77) with cellular C3a binding sites[2].
[1]. Payan DG, et al. Modulation of human lymphocyte function by C3a and C3a(70-77). J Exp Med. 1982 Sep 1;156(3):756-65. [2]. Caporale LH, et al. The active site of C3a anaphylatoxin. J Biol Chem. 1980 Nov 25;255(22):10758-63.
Kinase experiment: | 2×105 mononuelear leukocytes in 0.2 mL of M199-HPS containing 15% (vol/vol) AB-positive serum are added to each well of microtiter plates without or with 10 μg/mL of Con A, PHA, or SK-SD and incubated at 37°C in 5% CO2:95% air. C3a or C3a(70-77) is introduced into some suspensions at the same time as the stimulus or buffer. After 3 d for the mitogen-stimulated cultures and 5 d for the SK-SD-stimulated cultures, 1 μCi of [3H]thymidine is added to each well. After an additional 16 h at 37°C, the uptake of [3H]thymidine is analyzed by aspirating the contents of each well with a Mash II harvester that collected and ished the leukocytes on glass fiber filters. The radioactivity in each filter is quantified, and the results for quadruplicate chambers are expressed as mean cpm+SEM[1]. |
References: [1]. Payan DG, et al. Modulation of human lymphocyte function by C3a and C3a(70-77). J Exp Med. 1982 Sep 1;156(3):756-65. | |
| Cas No. | 63555-63-5 | SDF | |
| Canonical SMILES | Ala-Ser-His-Leu-Gly-Leu-Ala-Arg | ||
| Formula | C35H61N13O10 | M.Wt | 823.94 |
| 溶解度 | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2137 mL | 6.0684 mL | 12.1368 mL |
| 5 mM | 0.2427 mL | 1.2137 mL | 2.4274 mL |
| 10 mM | 0.1214 mL | 0.6068 mL | 1.2137 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *